UroGen Pharma Ltd.
NASDAQ:URGNBiotechnology
-$0.40 today
- Market cap
- $1.46B
- Beta
- 1.62
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$2.65
Volume 1.14M
Average 0.79M
URGN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
UroGen Pharma Ltd.NASDAQ: URGN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $15.6M fell 21.5% year over year, behind the +2.1% change in trailing-twelve-month research & development. Sequentially, it rose 9.0% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.
Context
- Research & development amounted to 61.1% of revenue in FY2025, down 2.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -21.5% toward the trailing-twelve-month pace of +2.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 67.11M USD
- Year-over-year change
- +17.4%
- 4-year CAGR
- +8.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 67.11M | +17.4% |
| FY2024 | 2024-12-31 | 57.15M | +25.3% |
| FY2023 | 2023-12-31 | 45.61M | -13.8% |
| FY2022 | 2022-12-31 | 52.91M | +11.0% |
| FY2021 | 2021-12-31 | 47.64M | — |
Research & Development vs competitors
How URGN compares with its peers on the latest reported figures
- URGN's LTM Mar 2026 research & development of $62.83M is the 2nd highest of the 3 companies compared; the peer median is $95.29M.
- Its year-over-year change of +2.1% is the 2nd highest of 3, against a peer median of -0.5%.
- Research & development amounts to 44.7% of revenue for URGN, versus a peer median of 2717.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $167.57M | +47.7% | +59.0% | 2717.6% | |
| LTM Mar 2026 | $62.83M | +2.1% | +8.2% | 44.7% | |
| LTM Mar 2026 | $23.02M | -48.6% | -81.3% | — | |
| Peer median (excluding URGN) | $95.29M | -0.5% | -11.1% | 2717.6% | |
Competitors are the stored peer set for URGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.04M | 64.36M | 82.71M | 90.4M | 109.79M |
| Cost of Revenue | 5.16M | 7.65M | 9.36M | 8.88M | 12.45M |
| Gross Profit | 42.89M | 56.7M | 73.35M | 81.52M | 97.34M |
| Gross Margin | 89.3% | 88.1% | 88.7% | 90.2% | 88.7% |
| Research & Development | 47.64M | 52.91M | 45.61M | 57.15M | 67.11M |
| Selling, General & Admin | 0 | 82.84M | 93.27M | 0 | 155.1M |
| Operating Expenses | 135.18M | 135.74M | 138.89M | 178.3M | 222.2M |
| Depreciation & Amortization | 831K | 1.82M | 1.71M | 329K | 2.41M |
| EBITDA | (108.54M) | (76.21M) | (60.35M) | (95.35M) | (135.66M) |
| EBITDA Margin | -225.9% | -118.4% | -73.0% | -105.5% | -123.6% |
| Operating Income | (92.29M) | (79.04M) | (65.54M) | (96.78M) | (124.86M) |
| Operating Margin | -192.1% | -122.8% | -79.2% | -107.1% | -113.7% |
| Interest Income | 365K | 938K | 2.64M | 8.9M | 5.97M |
| Interest Expense | 17.44M | 8.44M | 14.72M | 12.52M | 33.85M |
| Other Income / Expenses | (17.08M) | (28.99M) | (32.79M) | (27.26M) | (28.55M) |
| Income Before Tax | (109.37M) | (108.03M) | (98.32M) | (124.04M) | (153.42M) |
| Pre-Tax Margin | -227.7% | -167.9% | -118.9% | -137.2% | -139.7% |
| Income Tax Expense | 1.45M | 1.76M | 3.92M | 2.83M | 78K |
| Net Income | (110.82M) | (109.78M) | (102.24M) | (126.87M) | (153.49M) |
| Net Margin | -230.7% | -170.6% | -123.6% | -140.4% | -139.8% |
| EPS (Basic) | (4.96) | (4.79) | (3.55) | (2.96) | (3.19) |
| EPS (Diluted) | (4.96) | (4.79) | (3.55) | (2.96) | (3.19) |
| Weighted Avg Shares | 22.35M | 22.81M | 28.83M | 42.88M | 48.12M |
| Weighted Avg Shares (Diluted) | 22.35M | 22.81M | 28.83M | 42.88M | 48.12M |
UroGen Pharma Ltd.
NASDAQ:URGN
Intrinsic Alpha fair value
Locked
Current Price
$29.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.